Posted by Michael Wonder on 24 Sep 2019
Drug firms admit to colluding in order to keep prices up
20 September 2019 - Two suppliers of the antidepressant, nortriptyline, have admitted illegally sharing information in order to keep prices up.
The move comes as part of a competition law investigation by the Competition and Markets Authority (CMA) into drug firms King Pharmaceuticals Limited, Alissa Healthcare Research Limited and Lexon Limited.
In June 2019, the CMA issued a statement of objections provisionally finding that the 3 suppliers had exchanged commercially sensitive information about prices, volumes and entry plans in order to keep prices up.
